Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dr. S. A. Ziai Introduction Antipsychotic & neuroleptic Schizophrenia, psychoses & agitated states History Reserpine and chlorpromazine for more than.

Similar presentations


Presentation on theme: "Dr. S. A. Ziai Introduction Antipsychotic & neuroleptic Schizophrenia, psychoses & agitated states History Reserpine and chlorpromazine for more than."— Presentation transcript:

1

2 Dr. S. A. Ziai

3 Introduction Antipsychotic & neuroleptic Schizophrenia, psychoses & agitated states History Reserpine and chlorpromazine for more than 50 years The number of patients hospitalized has decreased Schizophrenia is now recognized as a biologic illness Nature of Psychosis & Schizophrenia The term "psychosis" denotes a variety of mental disorders Schizophrenia is a particular kind of psychosis characterized mainly by a clear sensorium but a marked thinking disturbance

4 1) many antipsychotic drugs strongly block postsynaptic D 2 receptors in the central nervous system, especially in the mesolimbic-frontal system; (2) drugs that increase dopaminergic activity, such as levodopa (a precursor), amphetamines (releasers of dopamine), and apomorphine (a direct dopamine receptor agonist), either aggravate schizophrenia or produce psychosis de novo in some patients (3) dopamine receptor density has been found postmortem to be increased in the brains of schizophrenics who have not been treated with antipsychotic drugs; (4) positron emission tomography (PET) has shown increased dopamine receptor density in both treated and untreated schizophrenics when compared with such scans of nonschizophrenic persons (5) successful treatment of schizophrenic patients has been reported to change the amount of homovanillic acid (HVA), a metabolite of dopamine, in the cerebrospinal fluid, plasma, and urine

5 They are only partially effective for most and ineffective for some patients Antagonists of the NMDA receptor such as phencyclidine, when administered to nonpsychotic subjects, produce much more "schizophrenia-like" symptoms than do dopamine agonists. Several of the atypical antipsychotic drugs have much less effect on D 2 receptors and yet are effective in schizophrenia

6 A. PHENOTHIAZINE DERIVATIVES Aliphatic derivatives (eg, chlorpromazine) and piperidine derivatives (eg, thioridazine) are the least potent. Piperazine derivatives are more potent (effective in lower doses) but not necessarily more efficacious. The piperazine derivatives are also more selective in their pharmacologic effects B. THIOXANTHENE DERIVATIVES Thiothixene In general, these compounds are slightly less potent than their phenothiazine analogs. C. BUTYROPHENONE DERIVATIVES Haloperidol is the most widely used, has a very different structure The butyrophenones and congeners tend to be more potent and to have fewer autonomic effects but greater extrapyramidal effects D. MISCELLANEOUS STRUCTURES The newer drugs pimozide, molindone, loxapine, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and aripiprazole

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21 Chemical ClassDrug D 2 /5- HT 2A Ratio Clinical Potency Extrapyramid al Toxicity Sedative Action Hypotensiv e Actions Phenothiazines AliphaticChlorpromazineHighLowMediumHigh PiperazineFluphenazineHigh LowVery low ThioxantheneThiothixene Very high HighMedium ButyrophenoneHaloperidolMediumHighVery highLowVery low DibenzodiazepineClozapineVery lowMediumVery lowLowMedium BenzisoxazoleRisperidoneVery lowHighLow Thienobenzodiaze pine OlanzapineLowHighVery lowMediumLow DibenzothiazepineQuetiapineLow Very lowMedium Low to medium DihydroindoloneZiprasidoneLowMediumVery lowLowVery low DihydrocarbostyrilAripiprazoleMediumHighVery low Low

22 ABSORPTION AND DISTRIBUTION Most readily but incompletely absorbed Many undergo significant first-pass metabolism Most antipsychotic drugs are highly lipid-soluble and protein- bound (92-99%). They have large volumes of distribution (usually > 7 L/kg). They generally have a much longer clinical duration of action than would be estimated from their plasma half-lives Full relapse may not occur until 6 weeks or more after discontinuation Most are almost completely metabolized Some metabolites retain activity but are weak The sole exception is mesoridazine

23 Chlorpromazine:  1 = 5-HT 2A > D 2 > D 1 Haloperidol: D 2 >  1 > D 4 > 5-HT 2A > D 1 > H 1 Clozapine: D 4 =  1 > 5-HT 2A > D 2 = D 1 Olanzapine: 5-HT 2A > H 1 > D 4 > D 2 >  1 > D 1 Aripiprazole: D 2 = 5-HT 2A > D 4 >  1 = H 1 >> D 1 Most of the atypical antipsychotic agents are at least as potent in inhibiting 5-HT 2 receptors as they are in inhibiting D 2 receptors Aripiprazole, appears to be a partial agonist of D 2 receptors

24 Adverse pharmacologic effects of antipsychotic drugs. TypeManifestationsMechanism Autonomic nervous system Loss of accommodation, dry mouth, difficulty urinating, constipation Muscarinic cholinoceptor blockade Orthostatic hypotension, impotence, failure to ejaculate Alpha adrenoceptor blockade Central nervous system Parkinson's syndrome, akathisia, dystonias Dopamine receptor blockade Tardive dyskinesia Supersensitivity of dopamine receptors Toxic-confusional stateMuscarinic blockade Endocrine system Amenorrhea-galactorrhea, infertility, impotence Dopamine receptor blockade resulting in hyperprolactinemia OtherWeight gain Possibly combined H 1 and 5-HT 2 blockade

25 Most antipsychotic drugs cause unpleasant subjective effects in nonpsychotic individuals Some of the neuroleptic agents lower the seizure threshold Galactorrhea, false-positive pregnancy tests, and increased libido have been reported in women Men have experienced decreased libido and gynecomastia Abnormal ECGs have been recorded, especially with thioridazine

26 Schizophrenia is the primary indication Many patients show little response and virtually none show a complete response They also indicated for schizoaffective disorders The psychotic aspects of the illness The manic phase in bipolar affective disorder often requires treatment with antipsychotic agents in severe olanzapine has been approved for this indication With antidepressants, psychotic depression

27 Nonmanic excited states may also be managed by antipsychotics, often in combination with benzodiazepines Tourette's syndrome Disturbed behavior in patients with Alzheimer's disease They are not indicated for the treatment of various withdrawal syndromes, eg, opioid withdrawal In small doses antipsychotics have been promoted (wrongly) for the relief of anxiety associated with minor emotional disorders

28 Most older antipsychotic drugs, with the exception of thioridazine, have a strong antiemetic effect Dopamine receptor blockade, both centrally (in the chemoreceptor trigger zone of the medulla) and peripherally (on receptors in the stomach) Some drugs, such as prochlorperazine and benzquinamide, are promoted solely as antiemetics Phenothiazines (shorter side chains) have considerable H 1 -blocker and have been used for relief of pruritus or, in the case of promethazine, as preoperative sedatives The butyrophenone droperidol is used in combination with an opioid, fentanyl, in neuroleptanesthesia

29 Choice is based mainly on differences in adverse effects and possible differences in efficacy New antipsychotic drugs have been shown in some trials to be more effective than older ones for treating negative symptoms (emotional blunting, social withdrawal, lack of motivation) Several of the newer antipsychotics, including clozapine, risperidone, and olanzapine, show superiority over haloperidol in terms of overall response in some controlled trials Older drugs that offer intramuscular formulations for acute and chronic treatment

30 Drug ClassDrugAdvantagesDisadvantages Phenothiazines AliphaticChlorpromazine 1 Generic, inexpensive Many adverse effects, especially autonomic PiperidineThioridazine 2 Slight extrapyramidal syndrome; generic 800 mg/d limit; no parenteral form; cardiotoxicity PiperazineFluphenazine 3 Depot form also available (enanthate, decanoate) (?) Increased tardive dyskinesia ThioxantheneThiothixene Parenteral form also available; (?) decreased tardive dyskinesia Uncertain ButyrophenoneHaloperidol Parenteral form also available; generic Severe extrapyramidal syndrome DibenzoxazepineLoxapine(?) No weight gainUncertain DibenzodiazepineClozapine May benefit treatment- resistant patients; little extrapyramidal toxicity May cause agranulocytosis in up to 2% of patients; dose-related lowering of seizure threshold

31 BenzisoxazoleRisperidone Broad efficacy; little or no extrapyramidal system dysfunction at low doses Extrapyramidal system dysfunction and hypotension with higher doses ThienobenzodiazepineOlanzapine Effective against negative as well as positive symptoms; little or no extrapyramidal system dysfunction Weight gain; dose- related lowering of seizure threshold DibenzothiazepineQuetiapine Similar to olanzapine; perhaps less weight gain May require high doses if there is associated hypotension; short t 1/2 and twice-daily dosing DihydroindoloneZiprasidone Perhaps less weight gain than clozapine, parenteral form available QT c prolongation DihydrocarbostyrilAripiprazole Lower weight gain liability, long half-life, novel mechanism potential Uncertain, novel toxicities possible

32 The range of effective dosages among various antipsychotics is quite broad Some patients who fail to respond to one drug may respond to another Differing profiles of receptor actions of the various drugs Patients who have become refractory to two or three antipsychotic agents given in substantial doses now become candidates for treatment with clozapine in dosages up to 900 mg/d, salvages about 30-50% of patients previously refractory to 60 mg/d of haloperidol Risperidone does not appear to substitute for clozapine, although reports are mixed

33 Well-tolerated High-potency older drugs Rapid initiation of treatment as well as for maintenance treatment in noncompliant patients Doses should be only a fraction of what might be given orally Fluphenazine decanoate 25 mg Haloperidol decanoate 5 mg Flupenthixol 20 mg

34 First, titrating to an effective dosage in divided daily doses After an effective daily dosage has been defined for an individual patient, doses can be given less frequently Once-daily doses, usually given at night

35 A very small minority require no further drug therapy for prolonged periods In most cases, the choice is between "as needed" increased doses or addition of other drugs The choice depends on social factors such as the availability of family or friends familiar with the symptoms of early relapse and ready access to care

36 Use of combinations is widespread TCAs or, more often, SSRIs Lithium or valproic acid is sometimes added to antipsychotic agents with benefit to patients who do not respond to the latter drugs alone misdiagnosed cases of mania or schizoaffective disorder? Sedative drugs may be added for relief of anxiety or insomnia not controlled by antipsychotics

37 A. BEHAVIORAL EFFECTS Pseudodepression that may be due to drug-induced akinesia B. NEUROLOGIC EFFECTS EPS: with older drugs and early during treatment Parkinson's syndrome, akathisia (uncontrollable restlessness Artan Self-limiting, so that an attempt to withdraw antiparkinsonism drugs should be made every 3-4 months Acute dystonic reactions (spastic retrocollis or torticollis) Diphenhydramine Tardive dyskinesia 20-40% of chronically treated patients Switch to one of the newer atypical agents Eliminate all drugs with central anticholinergic action (TCAs )

38

39 C. AUTONOMIC NERVOUS SYSTEM EFFECTS D. METABOLIC AND ENDOCRINE EFFECTS Weight gain is very common, especially with clozapine and olanzapine Hyperprolactinemia in women results in the amenorrhea- galactorrhea syndrome and infertility; in men, loss of libido, impotence, and infertility may result E. TOXIC OR ALLERGIC REACTIONS clozapine causes agranulocytosis in 1-2% weekly blood counts for the first 6 months of treatment and every 3 weeks thereafter F. OCULAR COMPLICATIONS Chlorpromazine deposits in the cornea and lens Thioridazine  retinal deposits  browning of vision

40 G. CARDIAC TOXICITY Overdoses of thioridazine are associated with major ventricular arrhythmias, cardiac conduction block, and sudden death H. USE IN PREGNANCY; DYSMORPHOGENESIS Relatively safe in pregnancy (must be decided individually) I. NEUROLEPTIC MALIGNANT SYNDROME In patients who are extremely sensitive to the extrapyramidal effects of antipsychotic agents Muscle rigidity (Creatine kinase isozymes are usually elevated) Sweating is impaired by anticholinergics The stress leukocytosis and high fever Autonomic instability, with altered blood pressure and pulse rate Vigorous treatment with antiparkinsonism drugs early in the course Muscle relaxants, particularly diazepam, are often useful, dantrolen and bromocriptine, have been reported to be helpful If fever is present, cooling by physical measures should be tried

41 Antipsychotics produce more important pharmacodynamic than pharmacokinetic interactions Thioridazine and ziprasidone-quinidine-like action

42 Poisonings with antipsychotics (unlike TCAs) are rarely fatal, with the exception of those due to mesoridazine and thioridazine Drowsiness proceeds to coma, with an intervening period of agitation Neuromuscular excitability may be increased and proceed to convulsions Pupils are miotic, and deep tendon reflexes are decreased Hypotension and hypothermia are the rule, though fever may be present later in the course.

43

44 Lithium carbonate Antimanic or "mood-stabilizing" agent Carbamazepine efective but not approved Valproate has recently been approved Atypical antipsychotics, beginning with olanzapine, are being investigated and approved as antimanic agents and potential mood stabilizers Grandiosity, bellicosity, paranoid thoughts, and overactivity Bipolar disorder has a strong familial component

45 Pharmacokinetics of lithium. Absorption Virtually complete within 6-8 hours; peak plasma levels in 30 minutes to 2 hours Distribution In total body water; slow entry into intracellular compartment. Initial volume of distribution is 0.5 L/kg, rising to L/kg; some sequestration in bone. No protein binding. MetabolismNone Excretion Virtually entirely in urine. Lithium clearance about 20% of creatinine. Plasma half-life about 20 hours. Target plasma concentration mEq/L Dosage0.5 mEq/kg/d in divided doses

46

47 (1) effects on electrolytes and ion transport It can substitute for sodium in generating action potentials (2) effects on neurotransmitters and their release (3) effects on second messengers and intracellular enzymes that mediate transmitter action

48 Lithium may uncouple receptors from their G proteins Polyuria and subclinical hypothyroidism Lithium can inhibit norepinephrine-sensitive adenylyl cyclase Antidepressant and antimanic effects

49 Until recently, lithium carbonate was the universally preferred treatment for bipolar disorder Slow onset of action of lithium The overall success is 80% but lower in hospitalized patients In maintenance it is 60% effective overall but less in severely ill patients The depressive phase TCA  precipitation of mania SSRIs  limited efficacy Bupropion  may induce mania at higher doses MAO  for some patients Lamotrigine  effective for many patients

50 Recurrent endogenous depression with a cyclic pattern is controlled by either lithium or imipramine Schizoaffective disorder -a mixture of schizophrenic symptoms and depression or excitement- is treated with antipsychotic drugs alone or combined with lithium. Antidepressants are added if depression is present In schizophrenia, adding it to an antipsychotic may salvage an otherwise treatment-resistant patient Carbamazepine may work equally With TCAs or SSRIs in patients with unipolar depression who do not respond fully to monotherapy with the antidepressant (low dose)

51 Measurements are customarily taken hours after the last dose First TDM obtained about 5 days after the start of treatment Simple arithmetic should produce the desired level Once the desired concentration has been achieved, levels can be measured at increasing intervals unless the schedule is influenced by intercurrent illness or the introduction of a new drug into the treatment program

52 Patients who have one or more episodes of illness per year are candidates for maintenance treatment Although some patients can be maintained with serum levels as low as 0.6 mEq/L, the best results have been obtained with higher levels, such as 0.9 mEq/L

53 Renal clearance of lithium is reduced about 25% by diuretics (eg, thiazides), and doses may need to be reduced by a similar amount A similar reduction in lithium clearance has been noted with several of the newer NSAIDs Not reported for either aspirin or acetaminophen All neuroleptics (except to clozapine and the newer antipsychotics) may produce more severe EPS when combined with lithium

54 NEUROLOGIC AND PSYCHIATRIC ADVERSE EFFECTS Tremor  Inderal or Tenormin Choreoathetosis, motor hyperactivity, ataxia, dysarthria, and aphasia DECREASED THYROID FUNCTION This effect is reversible or nonprogressive NEPHROGENIC DIABETES INSIPIDUS AND OTHER RENAL ADVERSE EFFECTS Occurring at therapeutic serum concentrations Long-term lithium therapy  chronic interstitial nephritis and nephrotic syndrome Patients receiving lithium should avoid dehydration EDEMA Edema is a common adverse effect and may be related to some effect of lithium on sodium retention

55 CARDIAC ADVERSE EFFECTS The bradycardia-tachycardia ("sick sinus") syndrome is a definite contraindication to the use of lithium because the ion further depresses the sinus node USE DURING PREGNANCY Renal clearance of lithium increases during pregnancy and needs dose reduction after delivery Lithium toxicity in newborns is manifested by lethargy, cyanosis, poor suck and Moro reflexes, and perhaps hepatomegaly In breast milk one-third to one-half that of serum MISCELLANEOUS ADVERSE EFFECTS Transient acneiform eruptions have been noted early in lithium treatment Folliculitis is less dramatic and probably occurs more frequently Leukocytosis by leukopoiesis

56 Common Some change in the patient's status, such as diminished serum sodium, use of diuretics, or fluctuating renal function Any value over 2 mEq/L must be considered as indicating likely toxicity Both peritoneal dialysis and hemodialysis are effective

57 Gabapentin is not effective Equivalent efficacy to that of lithium during the early weeks of treatment In some patients who have failed to respond to lithium Its side-effect profile is such that one can rapidly increase the dosage Nausea being the only limiting factor in some patients An appropriate first-line treatment for mania Is it effective as lithium in maintenance treatment ? Combining valproic acid and lithium in patients who do not fully respond to either agent alone

58 Oxcarbazepine is not effective Carbamazepine may be used to treat acute mania and also for prophylactic therapy Adverse effects are generally no greater and sometimes less than those associated with lithium It may be used alone or, in refractory patients, in combination with lithium or, rarely, valproate Blood dyscrasias not seen with its use as a mood stabilizer Overdoses are a major emergency and should generally be managed like overdoses of TCAs

59


Download ppt "Dr. S. A. Ziai Introduction Antipsychotic & neuroleptic Schizophrenia, psychoses & agitated states History Reserpine and chlorpromazine for more than."

Similar presentations


Ads by Google